Generics and Global Healthcare Spending: Key Economic Trends

Generics are medications that are identical to brand-name drugs but cost significantly less. They have been a cornerstone of affordable healthcare for decades, especially in a world where healthcare spending is rising rapidly.

The Rising Tide of Global Healthcare Spending

Global healthcare spending is on an upward trajectory, with the US alone projected to spend $5.6 trillion on healthcare by 2025. According to the Centers for Medicare and Medicaid Services (CMS), hospital spending will account for $1.8 trillion of that total. This growth is driven by aging populations, new medical technologies, and rising drug costs. However, the situation varies widely across countries. The global average public healthcare spending is just 3.8% of GDP, as reported by Human Rights Watch in 2025. In many low-income nations, this figure is far lower-some countries spend less than 1.2% of GDP on healthcare, leading to severe access issues.

How Generics Counterbalance Rising Costs

Generics play a critical role in managing these escalating costs. In the United States alone, generic drugs save patients and insurers over $1.1 trillion annually. Without generics, prescription drug costs would be significantly higher, placing immense strain on both individuals and healthcare systems.

IQVIA's 2023 report shows that the global pharmaceutical market is projected to grow at 3-6% annually through 2025. However, this growth is partially offset by the increasing use of generics. When patents expire on blockbuster drugs, generic versions enter the market, driving prices down by up to 90%. For example, when the patent for the cholesterol drug Lipitor expired, generic versions reduced costs by 95% within a year. This price reduction is a key reason why generics account for 80-90% of prescriptions in developed countries like the US and UK.

Regional Differences in Healthcare Financing

Out-of-Pocket Payments remain a major source of healthcare funding in many countries. Over 55 countries rely on out-of-pocket payments as their primary healthcare financing method. In Turkmenistan, Armenia, Afghanistan, and Nigeria, these payments exceed 75% of total healthcare spending.

According to the WHO Global Health Expenditure Database, 37 countries have seen declines in real public healthcare spending since the pandemic. Lebanon's healthcare spending dropped by 71%, while Malawi's fell by 41% between 2019 and 2021. These cuts make generic drugs even more vital for maintaining access to essential medicines. In contrast, high-income countries average 5.8% of GDP on healthcare, while low-income nations average just 1.2%. This disparity highlights why generic drugs are a lifeline in resource-constrained settings.

The Role of Biosimilars and New Drugs

Biosimilars are a newer class of drugs that mimic biologic medications. While they offer cost savings, their adoption varies widely due to regulatory differences and physician preferences. In the US, biosimilars for drugs like Humira have only recently entered the market, with limited uptake so far.

Despite the potential of biosimilars, many countries still face high drug costs. PwC's 2025 analysis shows that drug spending in the US grew by $50 billion in 2024, driven by specialty drugs for cancer, obesity, and diabetes. These areas often lack generic alternatives, leading to higher costs. However, as more biologics face patent expirations, biosimilars could play a larger role in reducing expenses. For example, the first biosimilar for Humira is expected to save $15 billion annually once fully adopted.

Generics in Developing Countries

Pharmaceutical Market dynamics in developing countries differ significantly from developed nations. In many low- and middle-income countries, generics make up over 90% of the medicine market. This is because they provide affordable alternatives where brand-name drugs are unaffordable for most people.

The Institute for Health Metrics and Evaluation reports that development assistance for health is expected to decline to $39.1 billion in 2025-the lowest level since 2009. This reduction in international aid makes domestic investment in generics even more critical. Countries like India and Brazil have become major producers of generic drugs, supplying affordable medications to millions worldwide. India alone exports generic drugs to over 150 countries, playing a pivotal role in global health.

However, challenges remain. In some regions, regulatory barriers and weak patent laws hinder generic production. For example, in parts of Africa, the lack of local manufacturing capacity forces reliance on imported generics, which can be expensive due to tariffs and transportation costs. Addressing these issues requires coordinated efforts between governments, pharmaceutical companies, and international organizations.

What the Future Holds

Drug Pricing remains a complex issue with regional variations. In the Middle East and Africa, medical costs are projected to grow by 12.1% in 2025-the highest among all regions. Meanwhile, Europe and Latin America show cooling trends, with costs rising only 6-7% annually.

The WTW Global Medical Trends Survey reveals that 67% of insurers expect higher demand for healthcare services in the next three years. This increased demand, coupled with rising costs, makes cost-effective treatments like generics even more critical. In the US, out-of-pocket prescription costs are projected to rise from $177 per person in 2025 to $231 by 2033. Generics will be essential to keep these costs manageable for patients.

Frequently Asked Questions